Drug Reimportation Rejected Again

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WASHINGTON-A second Secretary of Health and Human Services (HHS), Tommy G. Thompson, has refused to allow the reimporting of US-made prescription drugs back into the country. Former HHS Secretary Donna E. Shalala made the same determination last December.

WASHINGTON—A second Secretary of Health and Human Services (HHS), Tommy G. Thompson, has refused to allow the reimporting of US-made prescription drugs back into the country. Former HHS Secretary Donna E. Shalala made the same determination last December.

Under the Medicine Equity and Drug Safety (MEDS) Act, signed into law last year, US-made prescription drugs exported to certain foreign nations could be reimported for sale to US consumers. US medications sell for less abroad, and the law’s intent was that reimported drugs would be sold at below normal prices.

MEDS included a provision that required the HHS Secretary to determine that, if reimportation occurred, the United States could maintain adequate safety and prices could be expected to be reduced. Mr. Thompson found that would not be the case.

"Opening our borders as required under this program would increase the likelihood that the shelves of pharmacies across the nation would include counterfeit drugs, cheap foreign copies of FDA-approved drugs, expired drugs, contaminated drugs, and drugs stored under inappropriate and unsafe conditions," the Secretary said in a letter to Sen. James Jeffords (I-Vt).

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
2 experts are featured in this series.
2 experts are featured in this series.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Related Content